Dean Wingerchuk

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Neuromyelitis optica
    Dean M Wingerchuk
    Dean M Wingerchuk, MD, MSc, FRCP C Department of Neurology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Curr Treat Options Neurol 10:55-66. 2008
  2. doi Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic, Scottsdale, AZ Electronic address
    Mayo Clin Proc 89:225-40. 2014
  3. doi Neuromyelitis optica: potential roles for intravenous immunoglobulin
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
    J Clin Immunol 33:S33-7. 2013
  4. pmc A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis
    D M Wingerchuk
    Mayo Clinic, Scottsdale, Arizona, USA
    J Neurol Neurosurg Psychiatry 76:1294-6. 2005
  5. doi Hemi-meningitis: A focal sign heralding a multisystem necrotizing vasculitis
    Dean M Wingerchuk
    Department of Neurology, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    Neurology 70:2014. 2008
  6. doi Current evidence and therapeutic strategies for multiple sclerosis
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
    Semin Neurol 28:56-68. 2008
  7. ncbi Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management
    Dean M Wingerchuk
    Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Expert Rev Neurother 6:333-46. 2006
  8. ncbi Neuromyelitis optica
    D M Wingerchuk
    Multiple Sclerosis Center Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Int MS J 13:42-50. 2006
  9. ncbi The clinical course of acute disseminated encephalomyelitis
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Neurol Res 28:341-7. 2006
  10. ncbi Evidence for humoral autoimmunity in neuromyelitis optica
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Neurol Res 28:348-53. 2006

Detail Information

Publications68

  1. ncbi Neuromyelitis optica
    Dean M Wingerchuk
    Dean M Wingerchuk, MD, MSc, FRCP C Department of Neurology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Curr Treat Options Neurol 10:55-66. 2008
    ..We also recommend immunosuppression for at least 5 years in NMO-IgG seropositive patients presenting with a first-ever attack of longitudinally extensive transverse myelitis because they are at high risk for relapse or conversion to NMO...
  2. doi Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic, Scottsdale, AZ Electronic address
    Mayo Clin Proc 89:225-40. 2014
    ....
  3. doi Neuromyelitis optica: potential roles for intravenous immunoglobulin
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
    J Clin Immunol 33:S33-7. 2013
    ..The rationale and potential role for intravenous immunoglobulin in NMO will be discussed in the context of both relapse treatment and relapse prevention...
  4. pmc A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis
    D M Wingerchuk
    Mayo Clinic, Scottsdale, Arizona, USA
    J Neurol Neurosurg Psychiatry 76:1294-6. 2005
    ..Epidemiological and ecological studies suggest links between vitamin D deficiency and increased multiple sclerosis (MS) prevalence...
  5. doi Hemi-meningitis: A focal sign heralding a multisystem necrotizing vasculitis
    Dean M Wingerchuk
    Department of Neurology, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    Neurology 70:2014. 2008
  6. doi Current evidence and therapeutic strategies for multiple sclerosis
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
    Semin Neurol 28:56-68. 2008
    ....
  7. ncbi Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management
    Dean M Wingerchuk
    Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Expert Rev Neurother 6:333-46. 2006
    ..These skills will become increasingly important to those caring for MS patients as contemporary treatment regimens become increasingly complex...
  8. ncbi Neuromyelitis optica
    D M Wingerchuk
    Multiple Sclerosis Center Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Int MS J 13:42-50. 2006
    ..Relapsing NMO has a poor prognosis; therapy, typically with immunosuppression, is necessary as early as possible in the disease course to prevent attack-related disability...
  9. ncbi The clinical course of acute disseminated encephalomyelitis
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Neurol Res 28:341-7. 2006
    ....
  10. ncbi Evidence for humoral autoimmunity in neuromyelitis optica
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Neurol Res 28:348-53. 2006
    ..This evidence is reviewed in the context of its implications for future laboratory and clinical research in NMO...
  11. ncbi Revised diagnostic criteria for neuromyelitis optica
    D M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Neurology 66:1485-9. 2006
    ..A serum autoantibody marker, NMO-IgG, is highly specific for NMO. The authors propose revised NMO diagnostic criteria that incorporate NMO-IgG status...
  12. ncbi The spectrum of neuromyelitis optica
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Lancet Neurol 6:805-15. 2007
    ..The knowledge gained from further assessment of the exact role of NMO-IgG in the pathogenesis of neuromyelitis optica will provide a foundation for rational therapeutic trials for this rapidly disabling disease...
  13. ncbi Premenstrual multiple sclerosis pseudoexacerbations: Role of body temperature and prevention with aspirin
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA
    Arch Neurol 63:1005-8. 2006
    ..Many women with multiple sclerosis (MS) experience transient neurologic symptom worsening and fatigue in conjunction with the menstrual cycle. Aspirin reduces MS fatigue in some patients...
  14. ncbi Migraine with aura is a risk factor for cardiovascular and cerebrovascular disease: a critically appraised topic
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
    Neurologist 13:231-3. 2007
    ..To determine whether migraine with aura and migraine without aura are independent risk factors for symptomatic cardiovascular and cerebrovascular disease...
  15. ncbi A secondary progressive clinical course is uncommon in neuromyelitis optica
    D M Wingerchuk
    Department of Neurology, Mayo Clinic College of Medicine, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Neurology 68:603-5. 2007
    ..00002; relative risk = 0.08). The disparate natural histories of MS and NMO suggest dissociation between relapses and clinical progression in CNS demyelinating diseases...
  16. doi Neuromyelitis optica: effect of gender
    Dean M Wingerchuk
    Mayo Clinic College of Medicine, Scottsdale, AZ 85259, United States
    J Neurol Sci 286:18-23. 2009
    ..Population-based epidemiological and genetic studies, with case ascertainment aided by the high specificity of NMO-IgG and consistent disease definitions, are needed to better define and understand gender effects in neuromyelitis optica...
  17. ncbi Diagnosis and treatment of neuromyelitis optica
    Dean M Wingerchuk
    Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
    Neurologist 13:2-11. 2007
    ..Several clinical, laboratory, and neuroimaging characteristics may accurately distinguish NMO from MS early in the disease course...
  18. ncbi Multiple sclerosis: epidemiology, genetics, classification, natural history, and clinical outcome measures
    D M Wingerchuk
    Mayo Medical School, Rochester, Minnesota, USA
    Neuroimaging Clin N Am 10:611-24 ,vii. 2000
    ..This article reviews the current state of knowledge of MS epidemiology, genetics, disease classification, natural history, and outcome measures...
  19. ncbi Neuromyelitis optica: clinical predictors of a relapsing course and survival
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Neurology 60:848-53. 2003
    ..Early prediction of a relapsing course and subsequent disease severity would facilitate design and implementation of clinical trials of such therapies...
  20. ncbi Postinfectious encephalomyelitis
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA
    Curr Neurol Neurosci Rep 3:256-64. 2003
    ..The differences between childhood and adult ADEM, risks of development of multiple sclerosis, and the contributions of recent studies to refining the nosology of CNS demyelinating syndromes are discussed...
  21. ncbi Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis
    Dean M Wingerchuk
    Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
    Curr Opin Neurol 20:343-50. 2007
    ..We review recent progress in differentiating and understanding the disease mechanisms of acute disseminated encephalomyelitis, neuromyelitis optica, and classical multiple sclerosis...
  22. ncbi Neuromyelitis optica: current concepts
    Dean M Wingerchuk
    Multiple Sclerosis Center, Department of Neurology, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ 85259, USA
    Front Biosci 9:834-40. 2004
    ..Advances in understanding of its natural history and pathophysiology may eventually allow determination of whether idiopathic NMO represents a specific disease. This article summarizes recent progress in these areas of NMO research...
  23. ncbi Cannabis for medical purposes: cultivating science, weeding out the fiction
    Dean Wingerchuk
    Multiple Sclerosis Center, Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Lancet 364:315-6. 2004
  24. doi Environmental factors in multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smoking
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
    Mt Sinai J Med 78:221-30. 2011
    ..This review summarizes current evidence for these 3 putative multiple sclerosis risk factors and early attempts to develop risk models and examine gene-environment interactions for this complex disease...
  25. ncbi A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis
    D M Wingerchuk
    Department of Neurology Mayo Clinic, Scottsdale, AZ 85259, USA
    Neurology 64:1267-9. 2005
    ..012). There were no significant adverse effects. The results warrant further study and support a role for ASA-influenced mechanisms, perhaps immunologic, in the generation of MS-related chronic fatigue...
  26. ncbi Progressive cervical myelopathy secondary to chronic ventriculoperitoneal CSF overshunting
    D M Wingerchuk
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85255, USA
    Neurology 65:171-2. 2005
  27. doi Low serum vitamin D levels and recurrent inflammatory spinal cord disease
    Maureen A Mealy
    Department of Neurology, Johns Hopkins University, 600 N Wolfe Street, Baltimore, MD 21287, USA
    Arch Neurol 69:352-6. 2012
    ..As a sterol hormone involved in multiple immunologic pathways, vitamin D may play a role in preventing monophasic immune-mediated central nervous system attacks from developing into recurrent disease...
  28. ncbi Is there a neurologist on this flight?
    J I Sirven
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Neurology 58:1739-44. 2002
    ..To analyze the frequency of neurologic events during commercial airline flights and to assess whether onboard emergency medical kits are adequate for in-flight neurologic emergencies...
  29. ncbi A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis
    J H Noseworthy
    Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Neurology 56:1514-22. 2001
    ..To determine whether IV immunoglobulin (IVIg) reverses chronic visual impairment in MS patients with optic neuritis (ON)...
  30. doi NMO-IgG predicts the outcome of recurrent optic neuritis
    M Matiello
    Department of Neurology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Neurology 70:2197-200. 2008
    ..Recurrent ON may herald multiple sclerosis (MS) or NMO, or it may occur as an isolated syndrome. The prognosis and response to therapy differs in each of these contexts...
  31. ncbi Neuromyelitis optica: clinical syndrome and the NMO-IgG autoantibody marker
    B G Weinshenker
    Department of Neurology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55901, USA
    Curr Top Microbiol Immunol 318:343-56. 2008
    ....
  32. doi Neuromyelitis optica
    Mark J Morrow
    Department of Neurology, Harbor UCLA Medical Center, Torrance, CA, USA
    J Neuroophthalmol 32:154-66. 2012
    ..Hopefully, the future will bring more sensitive tools for defining risk and predicting outcome, as well as more targeted and effective forms of therapy...
  33. doi Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial
    Kathleen Hawker
    Department of Neurology, The Ohio State University Medical Center, Columbus, USA
    Ann Neurol 66:460-71. 2009
    ..We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety through 122 weeks...
  34. ncbi A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica
    Claudia F Lucchinetti
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Brain 125:1450-61. 2002
    ..Based on this study, future therapeutic strategies designed to limit the deleterious effects of complement activation, eosinophil degranulation and neutrophil/macrophage/microglial activation are worthy of further investigation...
  35. ncbi Epidemiology and natural history of multiple sclerosis: new insights
    Orhun Kantarci
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Curr Opin Neurol 19:248-54. 2006
    ..The cause of multiple sclerosis remains elusive. We review recent epidemiological studies of genetic and environmental factors that influence susceptibility to the disease and its clinical course...
  36. doi Is obstructive sleep apnea an independent risk factor for stroke? A critically appraised topic
    Dan J Capampangan
    Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA
    Neurologist 16:269-73. 2010
    ..Obstructive sleep apnea (OSA) is associated with hypertension, atrial fibrillation, coronary artery disease, congestive heart failure, and diabetes. These disorders are also risk factors for stroke...
  37. ncbi Multiple sclerosis: current pathophysiological concepts
    D M Wingerchuk
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
    Lab Invest 81:263-81. 2001
    ....
  38. ncbi Treatment of vascular dementia and vascular cognitive impairment
    Bart M Demaerschalk
    Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona 85259, USA
    Neurologist 13:37-41. 2007
    ..and vascular cognitive impairment, are acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and N-methyl-d-aspartate (NMDA) receptor antagonists (memantine) effective in improving cognitive function over placebo?..
  39. ncbi Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis
    Brian G Weinshenker
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Ann Neurol 59:566-9. 2006
    ..We investigated whether neuromyelitis optica (NMO) IgG seropositivity at the initial presentation of longitudinally extensive transverse myelitis (LETM) predicts relapse of myelitis or development of optic neuritis...
  40. ncbi OSMS is NMO, but not MS: proven clinically and pathologically
    Brian G Weinshenker
    Lancet Neurol 5:110-1. 2006
  41. ncbi Neuromyelitis optica
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
    Adv Neurol 98:319-33. 2006
  42. doi Establishing a diagnosis of benign paroxysmal positional vertigo through the dix-hallpike and side-lying maneuvers: a critically appraised topic
    Rashmi B Halker
    Department of Neurology, Division of Education Administration, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Neurologist 14:201-4. 2008
    ..Benign paroxysmal positional vertigo (BBPV) is one of the most common types of vertigo. Although the clinical presentation of this common condition is straightforward, the diagnosis and diagnostic maneuvers can be challenging...
  43. ncbi Acute disseminated encephalomyelitis: distinction from multiple sclerosis and treatment issues
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
    Adv Neurol 98:303-18. 2006
  44. ncbi Migraine with and without aura and risk for cardiovascular disease
    Bert B Vargas
    Department of Neurology, Mayo Clinic Hospital, 5777 East Mayo Boulevard, Phoenix, AZ 85054, USA
    Curr Atheroscler Rep 10:427-33. 2008
    ....
  45. ncbi Acute transverse myelitis: is the "idiopathic" form vanishing?
    Bruce A C Cree
    Neurology 65:1857-8. 2005
  46. ncbi Spinal cord astrocytoma presenting as "idiopathic" intracranial hypertension
    Alyx Porter
    Department of Neurology, Mayo Clinic, Rochester, 200 1st Street SW, Rochester, MN 55905, USA
    Clin Neurol Neurosurg 108:787-9. 2006
    ..This case illustrates that increased intracranial pressure may in exceptional cases of spinal tumors precede the more typical myelopathic presentation by months and mimic idiopathic intracranial hypertension...
  47. ncbi Practical consultations: multiple sclerosis
    Dean M Wingerchuk
    Multiple Sclerosis Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Semin Neurol 23:253-64. 2003
    ..A general approach, supported by evidence where possible, to common and contemporary clinical issues in MS care is provided in a case-based narrative...
  48. ncbi Remission, intractability, and antiepileptic-drug withdrawal
    Dean M Wingerchuk
    Lancet Neurol 4:390-1. 2005
  49. ncbi Seizure prophylaxis in patients with brain tumors: a meta-analysis
    Joseph I Sirven
    Department of Neurology Mayo Clinic College of Medicine, Scottsdale, Ariz, USA
    Mayo Clin Proc 79:1489-94. 2004
    ..To assess whether antiepileptic drugs (AEDs) should be prescribed to patients with brain tumors who have no history of seizures...
  50. ncbi A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
    Vanda A Lennon
    Department of Neurology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Lancet 364:2106-12. 2004
    ..We assessed the capacity of a putative marker for neuromyelitis optica (NMO-IgG) to distinguish neuromyelitis optica and related disorders from multiple sclerosis...
  51. ncbi Brain abnormalities in neuromyelitis optica
    Sean J Pittock
    Department of Neurology, Laboratory Medicine and Pathology, Radiology, and Immunology, Mayo Clinic College of Medicine, Rochester, Minn, USA
    Arch Neurol 63:390-6. 2006
    ..We have, however, frequently encountered patients with a well-established diagnosis of NMO in whom either asymptomatic or symptomatic brain lesions develop suggesting that the diagnostic criteria for NMO should be revised...
  52. ncbi Not every patient with multiple sclerosis should be treated at time of diagnosis
    Sean J Pittock
    Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Arch Neurol 63:611-4. 2006
  53. doi Neuromyelitis optica and non organ-specific autoimmunity
    Sean J Pittock
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Arch Neurol 65:78-83. 2008
    ..Neuromyelitis optica (NMO) is often associated with other clinical or serological markers of non-organ-specific autoimmunity...
  54. ncbi Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis
    Shanu F Roemer
    Department of Neurology, Mayo Clinic, College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Brain 130:1194-205. 2007
    ..These findings strongly support a role for a complement activating AQP4-specific autoantibody as the initiator of the NMO lesion, and further distinguish NMO from MS...
  55. ncbi Second-generation antiepileptic drugs' impact on balance: a meta-analysis
    Joseph I Sirven
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Ariz, USA
    Mayo Clin Proc 82:40-7. 2007
    ..To systematically review available evidence regarding whether second-generation antiepileptic drugs (AEDs) contribute to the risk of balance disorders...
  56. ncbi Neuromyelitis optica
    Marcelo Matiello
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Curr Opin Neurol 20:255-60. 2007
    ..We concentrate on a recently identified serum antibody biomarker, neuromyelitis optica immunoglobulin G (NMO-IgG), which distinguishes neuromyelitis optica from multiple sclerosis...
  57. ncbi Alpha-lipoic acid may improve symptomatic diabetic polyneuropathy
    Junger Tang
    Department of Neurology, Mayo Clinic Rochester, Rochester, MN, USA
    Neurologist 13:164-7. 2007
    ..In patients with symptomatic diabetic polyneuropathy, is oral alpha-lipoic acid (ALA) effective in improving neuropathic symptoms compared with placebo?..
  58. ncbi Neuromyelitis optica: new findings on pathogenesis
    Dean M Wingerchuk
    Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
    Int Rev Neurobiol 79:665-88. 2007
    ..Other immunologic differences among NMO, NMO-spectrum disorders, and classical MS are reviewed...
  59. doi Does cervical manipulative therapy cause vertebral artery dissection and stroke?
    Madeline L Miley
    Division of Neurosciences, Faculty of Science, Loyola University, Chicago, IL, USA
    Neurologist 14:66-73. 2008
    ..Does cervical manipulative therapy (CMT) cause vertebral arterial dissection (VAD) and subsequent ischemic stroke? What is the best estimate of the incidence of CMT associated with VAD and ischemic stroke?..
  60. pmc NMO-IgG: a specific biomarker for neuromyelitis optica
    Brian G Weinshenker
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Dis Markers 22:197-206. 2006
    ....
  61. ncbi Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders?
    Jonathan H McKinnon
    Department of Neurology, Mayo Clinic College of Medicine, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
    Neurologist 13:382-5. 2007
    ..A recent American Academy of Neurology practice parameter indicated that olfactory testing was "probably useful" for differentiating idiopathic Parkinson disease (IPD) from other diseases with features of parkinsonism...
  62. ncbi Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression
    Sean J Pittock
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905 0001, USA
    Arch Neurol 63:964-8. 2006
    ..Although it is conventionally believed that the brain is spared, brain imaging abnormalities are not uncommon in patients with NMO...
  63. ncbi Randomized controlled trials to assess therapies for multiple sclerosis
    Dean M Wingerchuk
    Department of Neurology, Mayo Clinic and Mayo Foundation, Scottsdale, AZ 55905, USA
    Neurology 58:S40-8. 2002
    ....
  64. ncbi "Idiopathic" rapid-eye-movement (REM) sleep behavior disorder is associated with future development of neurodegenerative diseases
    Mark G Hickey
    Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona 85259, USA
    Neurologist 13:98-101. 2007
    ..To determine whether a diagnosis of idiopathic rapid-eye-movement sleep behavior disorder (RBD) is associated with a future risk of development of neurodegenerative diseases...
  65. ncbi The MERITs of evidence-based clinical practice in neurology
    Bart M Demaerschalk
    Mayo Clinic College of Medicine, Scottsdale, Arizona 85255, USA
    Semin Neurol 27:303-11. 2007
    ....
  66. ncbi Critically appraised topics: the evidence-based neurologist
    Dean M Wingerchuk
    Neurologist 13:1. 2007
  67. ncbi Neuromyelitis optica: changing concepts
    Anu Jacob
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Neuroimmunol 187:126-38. 2007
    ..The development of animal models and further analysis of the association of NMO-IgG with disease severity and treatment response will elucidate the pathobiology of NMO...
  68. doi Clinical predictors of psychogenic nonepileptic seizures: a critically appraised topic
    Matthew T Hoerth
    Department of Neurology, Division of Education Administration, Mayo Clinic, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA
    Neurologist 14:266-70. 2008
    ..Identification of clinical features that reliably distinguish PNES from ES would be valuable in acute care settings, for patients that have coexisting disorders, and those with multiple event types...